Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | 2024 | YoY |
|---|---|---|
| Revenue | 215.66M | 3.65% |
| Gross profit | 131.79M | 8.97% |
| Net profit | -12.94M | 66.09% |
| EBITDA | 4.66M | 113.98% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €417.44M |
Number of shares | 540.57M |
52-week high/low | €0.79 - €0.29 |
| Dividends | No |
Beta | 0.58 |
P/E ratio | -32.51 |
PEG ratio | -0.33 |
P/B ratio | 1.68 |
P/S ratio | 1.96 |
Company profile
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
| Name | ALLIANCE PHARMA LS-,01 |
| CEO | Nicholas John Sedgwick |
| Headquarters | Chippenham,
United Kingdom |
| Website | |
| IPO | 11/22/2001 |
| Employees | 290 |
Ticker symbols
| Exchange | Symbol |
|---|---|
London Stock Exchange | APH.L |
Frankfurt | DVL.F |
London | APH.L |
München | DVL.MU |
Düsseldorf | DVL.DU |